Persistence with treatment for Wilson disease: a retrospective study.

Abstract

BACKGROUND:

Wilson disease (WD) is genetically induced failure of copper metabolism which can be successfully treated with pharmacological agents. The prognosis for survival in most WD patients is favorable if diagnosis and anti-copper treatment are provided early. Many observations imply that persistence with drug treatment is generally low in patients with chronic diseases, which impact the treatment effectiveness, but such results are very limited in WD. The aim of our study was to assess persistence with treatment among WD patients, to analyze its effect on patient outcome and to identify factors that might be related to persistence.

METHODS:

170 newly diagnosed, symptomatic patients with WD who started treatment between 1995 and 2005 were analyzed retrospectively to assess treatment non-persistence, which was defined as at least one reported break of more than 3 months or minimum two breaks lasting longer than 2 months. Results were further analyzed according to selected clinical variables.

RESULTS:

Only 74.1% of patients were persistent with treatment during the mean 11.7 years of follow up. Treatment persistence closely impacted positive clinical outcomes. In patients classified as persistent, improvement and lack of WD progression were observed more often compared to those classified as non-persistent (29.4 and 68.3% vs. 2.3 and 45.5%; p < 0.001, respectively). In contrast, non-persistent patients presented more often with worsening WD than persistent patients (52.3% vs. 2.4%). Type of WD treatment, gender, phenotypic presentation, adverse events and duration of treatment were not related to treatment persistence. Higher or upper/post-secondary education and a supportive family attitude towards treatment were the most important factors related to persistence.

CONCLUSIONS:

One quarter of WD patients were not taking anti-copper treatment regularly and this had an important negative effect on clinical outcome. Family support played an important role in treatment persistence.

• Authors: Wojciech Masełbas, Anna Członkowska, Tomasz Litwin, Maciej Niewada
• Journal: BMC neurology (BMC Neurol) Vol. 19 Issue 1 Pg. 278 (Nov 12 2019) ISSN: 1471-2377 [Electronic] England
• PMID: 31718567 (Publication Type: Journal Article, Observational Study)

Chemical References

• Chelating Agents
• Zinc Sulfate
• Penicillamine

Topics

• Adult
• Chelating Agents (therapeutic use)
• Female
• Hepatolenticular Degeneration (drug therapy)
• Humans
• Male
• Medication Adherence (statistics & numerical data)
• Penicillamine (therapeutic use)
• Poland
• Retrospective Studies
• Zinc Sulfate (therapeutic use)